Results 141 to 150 of about 71,664 (187)

Association Between Body Mass Index and Cardiac Dysfunction During Human Epidermal Growth Factor Receptor 2 Inhibitor Therapy for Breast Cancer. [PDF]

Circ Rep
Masaki M, Horie T, Wakasa M, Yamaguchi K, Saeki Y, Ishigaki Y, Sakurai M, Inokuchi M, Tsuchiya T.   +8 more
europepmc   +1 more source

Disulfide rebridging platforms for site-specific ADC conjugation. [PDF]

RSC Chem Biol
Petri L, Kovács ÍK, Kiss BJ, Keserű GM.   +3 more
europepmc   +1 more source

Case Report: Non-invasive [⁸⁹Zr]Zr-DFO-trastuzumab positron emission tomography in the multimodal characterisation of platinum-resistant high-grade serous ovarian cancer. [PDF]

Front Nucl Med
Ferreira Machado JDM, Winzer R, Apolle R, Forberger A, Zarschler K, Knieß T, Kreller M, Kopka K, Kiß OC, Kuhlmann JD, Wimberger P, Miederer M, Link T.   +12 more
europepmc   +1 more source

From Payload-First Toward Dual-Mechanism Antibody-Drug Conjugates. [PDF]

Adv Mater
Pivot X, Jung S, Harlepp S, Detappe A.
europepmc   +1 more source

Patient-reported outcomes and targeted therapeutic escalation in NRG Oncology/RTOG 1010: When intensification fails to translate to improved outcomes. [PDF]

Cancer
Brown TJ, Hornstein NJ, Grewal US, Sanford NN.   +3 more
europepmc   +1 more source

HER2-directed therapy with Trastuzumab deruxtecan in recurrent mucinous ovarian carcinoma: complete clinical response and response to rechallenge. [PDF]

Gynecol Oncol Rep
Krivenko O, Diaz N, Marcus J, Musa F.
europepmc   +1 more source

Modular in vivo antibody-ADC click to reverse drug resistance in tumours. [PDF]

Nature
Simó C, Vanover AC, D'Oliveira Albanus R, Panikar SS, Shmuel S, Benton A, Giraldo-Guzman J, Luna JM, Xu Y, Berry NK, Keltee N, Liu J, Dehdashti F, Pereira PMR.   +13 more
europepmc   +1 more source

Clinical management of adverse events in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer treated with tucatinib, trastuzumab, and capecitabine. [PDF]

Oncologist
Okines AFC, Roesch E, Watkins K, Pitner MK, Hutchinson KM, Simon S, Yan F.   +6 more
europepmc   +1 more source

Impact of adjuvant endocrine therapy on disease-free survival in early triple-positive breast cancer: a multicenter retrospective cohort study of the Turkish oncology group. [PDF]

BMC Cancer
Seyyar M, Şancı PC, Doğan A, Biter S, Köşeci T, Balçık OY, Karabel SS, Kalem A, Akosman C, Pilancı KN, Onur İD, Arslan ÜY, Kemal Y, Avcı T, Şahbazlar M, Akay S, Kahraman EG, Bayramgil A, Altıntaş YE, Tünbekici S, Göker E, Çolak C, Demir T, Demirağ G, Güneysu GG, Aykan MB, Nazlı İ, Alkan O, Ökten İN, Çolak R, Yılmaz M, Gür HB, Hacıbekiroğlu İ, Sönmez M, Özyurt N, Aydın O, Ertürk K, Şahin E, Karakayalı A, Baydar E, Çıtakkul İ, Emin G, Yıldırım A, Gülmez A, Özberk U, Algın E, Köseoğlu Ç, Uzundere FK, Urakçı Z, Akpunar M, Alkan A, Süner A, Peker P, Camadan YA, Can LŞ, Telli TA, Majidova N, Uzun M, Özkan MK, Baykara M, Güzel HG, Yıldırım HÇ, Kefeli U, Çabuk D, Kus T.   +64 more
europepmc   +1 more source

Research Advances in Drug Resistance Mechanisms to Anti-HER2 Therapy in HER2-Positive Breast Cancer. [PDF]

Oncol Res
Huang C, Kong J, Ren H, Zhang W, Jiang S, Sheng X.   +5 more
europepmc   +1 more source